Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Gross Margin (2018 - 2025)

Historic Gross Margin for Agios Pharmaceuticals (AGIO) over the last 8 years, with Q3 2025 value amounting to 86.96%.

  • Agios Pharmaceuticals' Gross Margin fell 43000.0% to 86.96% in Q3 2025 from the same period last year, while for Sep 2025 it was 87.22%, marking a year-over-year decrease of 21600.0%. This contributed to the annual value of 88.59% for FY2024, which is 6700.0% down from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Gross Margin stood at 86.96%, which was down 43000.0% from 86.33% recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Gross Margin registered a high of 92.34% during Q1 2024, and its lowest value of 59.25% during Q1 2022.
  • Moreover, its 4-year median value for Gross Margin was 88.26% (2024), whereas its average is 86.62%.
  • The largest annual percentage gain for Agios Pharmaceuticals' Gross Margin in the last 5 years was 308700bps (2023), contrasted with its biggest fall of -87100bps (2023).
  • Over the past 4 years, Agios Pharmaceuticals' Gross Margin (Quarter) stood at 90.42% in 2022, then grew by 1bps to 91.75% in 2023, then dropped by -4bps to 88.26% in 2024, then dropped by -1bps to 86.96% in 2025.
  • Its Gross Margin was 86.96% in Q3 2025, compared to 86.33% in Q2 2025 and 87.57% in Q1 2025.